Form D · Biotechnology
Cascade Biocatalysts, Inc.
Denver, CO · CIK 0002083126
Offering snapshot reported Aug 25, 2025 · SEC filing
- Reported sold
- $5.44M Offering amount: $5.62M
- Investors reported
- 41 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 8, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2025 | Initial | $5,441,785 | No comparison | 41 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-555703
Source: Form D, filed Aug 25, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jared Campbell | Director |
| Alexander Rosay | Director, Executive, Promoter |
| James Weltz | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3960 Niagara Street Suite B
Denver, CO, 80207
Denver, CO, 80207